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he 
 
 
 
v
 
 
 
3
 
 integrin has been shown to promote cell mi-
gration through activation of intracellular signaling
pathways. We describe here a novel pathway that
modulates cell migration and that is activated by 
 
 
 
v
 
 
 
3
 
 and,
as downstream effector, by cdc2 (cdk1). We report that
 
 
 
v
 
 
 
3
 
 expression in LNCaP (
 
 
 
3
 
-LNCaP) prostate cancer
cells causes increased cdc2 mRNA levels as evaluated by
gene expression analysis, and increased cdc2 protein and
kinase activity levels. We provide three lines of evidence
that increased levels of cdc2 contribute to a motile pheno-
type on integrin ligands in different cell types. First, increased
levels of cdc2 correlate with more motile phenotypes of
T
 
cancer cells. Second, ectopic expression of cdc2 increases
cell migration, whereas expression of dominant-negative
cdc2 inhibits migration. Third, cdc2 inhibitors reduce cell
migration without affecting cell adhesion. We also show
that cdc2 increases cell migration via speciﬁc association
with cyclin B2, and we unravel a novel pathway of cell
motility that involves, downstream of cdc2, caldesmon.
cdc2 and caldesmon are shown here to localize in membrane
rufﬂes in motile cells. These results show that cdc2 is a
 
downstream effector of the 
 
 
 
v
 
 
 
3
 
 integrin, and that it promotes
cell migration.
 
Introduction
 
Cell–ECM interactions are predominantly mediated by inte-
grins (Hynes, 1999). The 
 
 
 
v
 
 
 
3
 
 integrin is predominantly,
although not exclusively, found in cancer cells and neovessels
(for review see Byzova et al., 1998; Seftor et al., 1999). Expres-
sion of 
 
 
 
v
 
 
 
3
 
 in tumor cells alters cell–ECM interactions and
causes increased tumorigenicity (Felding-Habermann et al.,
1992), as well as invasiveness of several cancer cells. 
 
 
 
v
 
 
 
3
 
 has
been shown to contribute to the establishment and growth
of pulmonary metastatic melanoma lesions (Filardo et al.,
1995), and to increased invasiveness of cutaneous melanomas
from the epidermis to the dermis (Hsu et al., 1998) and of
human breast cancer cells in nude mice (Felding-Habermann
et al., 2001).
Cell migration mediated by integrins, a crucial step in in
vivo metastasis establishment and growth, has been shown
in vitro to be supported by multiple downstream signaling
pathways (Schwartz et al., 1995). Although activation of
these pathways is a prerequisite for cell migration, changes in
gene expression are also likely to play a role in cell invasion.
As shown recently by several groups, alterations of gene
expression occur in response to integrin binding to ECM
proteins (Damsky and Werb, 1992; Ruoslahti and Reed, 1994;
Juliano, 1996). Cell adhesion has been shown to increase the
levels of cyclin A mRNA and protein (Guadagno et al., 1993),
cyclin D1 mRNA and protein (Zhu et al., 1996), cyclin E-cdk2
kinase activity (Fang et al., 1996; Zhu et al., 1996), gelatinase
in T cells becoming transmigratory (Romanic and Madri,
1994), metalloproteinases in fibroblasts (Werb et al., 1989;
Huhtala et al., 1995), immediate–early response genes, as well
as transcription factors in monocytes responding to injury or
infection (for review see Juliano and Haskill, 1993), and more
than 32 genes identified in salivary epithelial cells undergoing
morphological differentiation (Lafrenie and Yamada, 1998;
Lafrenie et al., 1998). In addition to a requirement for integrin
engagement, it has been consistently highlighted that specific
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integrins uniquely affect gene expression. Among 
 
 
 
1
 
 integrins,
it has been shown that 
 
 
 
1
 
 and 
 
 
 
2
 
, but not 
 
 
 
6
 
, integrins specif-
ically regulate stromelysin-1 expression in mouse mammary
carcinoma cells (Lochter et al., 1999). Similarly, 
 
 
 
v
 
 
 
3
 
-induced
gene expression in response to cell adhesion to 
 
 
 
v
 
 
 
3
 
 ligands
has been documented in several instances. Binding of dena-
tured collagen to 
 
 
 
v
 
 
 
3
 
 in smooth muscle cells induces tenas-
cin-C expression during vascular remodeling (Jones et al.,
1999). A different work showed that antibodies to 
 
 
 
v
 
 
 
3
 
, but
not to 
 
 
 
5
 
 
 
1
 
, increase the invasive ability of a melanoma cell
line endogenously expressing 
 
 
 
v
 
 
 
3
 
 concurrent with an induc-
tion of type IV collagenase mRNA and protein (Seftor et al.,
1992). Furthermore, cell adhesion mediated by 
 
 
 
v
 
 
 
3
 
 and
 
 
 
5
 
 
 
1
 
, but not 
 
 
 
v
 
 
 
1
 
, has been shown to regulate bcl-2 tran-
scription (Matter and Ruoslahti, 2001).
The increased invasive behavior of neoplastic cells that oc-
curs in response to 
 
 
 
v
 
 
 
3
 
 integrin expression can be explained
on the basis of a unique 
 
 
 
v
 
 
 
3
 
-activated cellular response that
may positively regulate cell migration. We searched for
downstream effectors of 
 
 
 
v
 
 
 
3
 
 in prostate cancer cells where
 
 
 
v
 
 
 
3
 
 expression correlates with a neoplastic and migratory
phenotype (Zheng et al., 1999). Here, we show that 
 
 
 
v
 
 
 
3
 
 in-
tegrin expression in LNCaP prostate cancer cells up-regu-
lates cdc2 mRNA and protein levels, as well as cdc2 kinase
activity. We demonstrate a new role for cdc2 in cell motility
on integrin ligands and unravel a novel mechanism of cell
motility mediated by cdc2, its cofactor cyclin B2 and, down-
stream of cdc2, caldesmon, a molecule known to be associ-
ated with the cytoskeleton. Together, these data show that
cdc2 is a downstream effector of 
 
 
 
v
 
 
 
3
 
 and that it promotes
cell migration.
 
Results
 
 
 
v
 
 
 
3
 
 integrin up-regulates cdc2 mRNA, protein, 
and kinase levels
 
In an attempt to determine genes regulated by the 
 
 
 
v
 
 
 
3
 
integrin, which contribute to this phenotype in cancer
cells, a gene expression analysis was undertaken. As a
model system, LNCaP prostate cancer cells were stably
transfected with expression vector containing human 
 
 
 
3
 
integrin cDNA, or empty expression vector (mock), or ex-
pression vector containing human ICAM-1 cDNA as a
transfection control for the effects of ectopically express-
ing a cell surface protein. Expression of 
 
 
 
v
 
 
 
3
 
 integrin in
three different cell populations (
 
 
 
3
 
-1, 
 
 
 
3
 
-2, and 
 
 
 
3
 
-3), as
well as ICAM expression in two different populations, was
confirmed by FACS
 
®
 
 analysis (Fig. 1 A; unpublished data;
Zheng et al., 1999).
First-strand cDNA of mRNA isolated from 
 
 
 
3
 
-LNCaP,
ICAM-LNCaP, and mock-LNCaP cells were used as probes
on cDNA array filters containing 588 human genes known
to be disregulated in cancer. Only those genes that displayed
at least a threefold difference in expression between 
 
 
 
3
 
- and
mock-LNCaP cells (Fig. 1 B), or 
 
 
 
3
 
- and ICAM-LNCaP
cells (unpublished data) were considered as legitimate targets
of 
 
 
 
v
 
 
 
3
 
 integrin–mediated expression. Among others, cdc2
was specifically up-regulated in 
 
 
 
3
 
-LNCaP cells (Fig. 1 B).
Because cdc2 is a prognostic indicator of prostate tumor
progression (Kallakury et al., 1997), further investigation of
the expression of this gene was undertaken. Northern blot
analysis was performed to verify the cDNA expression array
results (unpublished data).
Figure 1. cdc2 mRNA, protein, and kinase levels are 
increased in  3-LNCaP cells. (A) Surface expression of ectopic 
 v 3 integrin in LNCaP cell stable transfectants. Mock-,  3-1, 
 3-2, and  3-3 LNCaP cells were incubated with mAb to  v 3 
integrin (AP-3, thick line) or, as negative control, to the HA 
epitope (12CA5, thin line) followed by staining with FITC-
conjugated goat anti–mouse Ig antibody and analysis using 
a FACScan
TM flow cytometer. (B) cDNA expression array 
analysis. First strand cDNA probes prepared with either  3-1 
or mock-LNCaP mRNA were hybridized to Atlas human 
cancer cDNA expression arrays. Shown are areas of section 
A of the cDNA array membrane. The arrow indicates the 
spots corresponding to cdc2 on the array. The brackets 
indicate other genes on the array that are not up-regulated in 
 3-1. (C–F) cdc2 protein and kinase levels are increased in 
 3-LNCaP cells grown in 2D (C and D) and 3D (E and F) 
cultures. (C) cdc2 protein levels in extracts from LNCaP cell 
transfectants grown in 2D culture were analyzed by IB with 
an antibody to cdc2. In C and E, antibody to ERK-1 was used 
for protein loading control. (D) Immunocomplexes precipitated 
from 75  g of  3-1,  3-3,  3-2, ICAM-, or mock-LNCaP cell 
extracts using an mAb to cdc2 were used in a kinase reaction 
using histone H1 as a substrate. Consistent results were 
obtained in two additional experiments. (E) cdc2 protein 
levels in extracts from LNCaP cell transfectants grown in 3D 
Matrigel culture for 48 h were analyzed by IB with an antibody 
to cdc2. (F) Immunocomplexes precipitated from 75  g of 
 3-1,  3-2, ICAM-, or mock-LNCaP cell extracts using an 
mAb to cdc2 were used in a kinase reaction using histone H1 
as a substrate. Consistent results were obtained in two 
additional experiments.T
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Using extracts prepared from  3-, ICAM-, and mock-
LNCaP cells, we observed up-regulation of cdc2 protein in
 3-LNCaP cells as compared with mock- and ICAM-LNCaP
cells (Fig. 1 C). Also shown in Fig. 1 C are cdc2 levels in ex-
tracts from LNCaP cells stably transfected with an expres-
sion vector containing the human  6 integrin subunit
cDNA ( 6-LNCaP clones:  6-1 and  6-2). The  6 integrin
subunit was chosen because, like  3, it is not expressed in
LNCaP cells (unpublished data) and it also heterodimerizes
with  v and shares several ligands with  v 3 (Busk et al.,
1992; Huang et al., 1998). The results show that cdc2 levels
in two clones expressing  v 6 are significantly lower than in
 3-LNCaP cells.  3-LNCaP cells display increased cdc2 ki-
nase activity compared with mock- and ICAM-LNCaP cells
(Fig. 1 D), as well as  6-LNCaP cells (unpublished data).
cdc2 protein and kinase levels were also increased in three-
dimensional (3D)* Matrigel cultures in  3-LNCaP cells
compared with mock- and ICAM-LNCaP cells (Fig. 1, E
and F, respectively).
Overall, the results show that the  v 3 integrin expression
in LNCaP cells specifically up-regulates cdc2 mRNA, pro-
tein, and kinase levels.
Correlation of cdc2 expression and cell migration
Because several molecules known to affect cell cycle progres-
sion or proliferation such as FAK and PI3K are positive
modulators of cell migration (Cary et al., 1996; Keely et al.,
1997; Shaw et al., 1997), it was hypothesized that the in-
creased cdc2 protein and kinase levels might play a role in
LNCaP cell migration. A correlation between cdc2 levels
and more migratory phenotypes on integrin ligands was ob-
served between a human fibrosarcoma cell line (HT1080)
and a genetically modified variant cell line (HT2–19). In the
latter, one cdc2 allele has been deleted, and the other placed
under the control of an inducible promoter; removal of
IPTG suppresses expression of the remaining allele (Itzhaki
et al., 1997). Lower levels of cdc2 in HT2–19 cells corre-
lated with a reduction in migration on fibronectin (FN; P  
2   10
 8), under conditions in which they attached equally
well to FN (Fig. 2). When HT2–19 cells were cultured in
the absence of IPTG to suppress cdc2 expression, these cells’
migration was further reduced (67% less than in the pres-
ence of IPTG, P   2   10
 5; Fig. 2). The results show that
increased levels of cdc2 correlate with a more migratory phe-
notype on integrin ligands.
Inhibition of cdc2 kinase prevents LNCaP cell migration
Transient expression of a dominant-negative variant of
cdc2 (cdc2dn) was used to determine whether cdc2 had an
effect on migration of LNCaP cells (Fig. 3 A). The data
show that cdc2dn significantly inhibits cell migration on
FN. Comparable results were obtained using cells sus-
pended in 0.5% (Fig. 3 A) or 10% FBS (Fig. 3 B); there-
fore, 0.5% or 10% FBS were interchangeably used in our
paper. Ectopic expression of cdc2dn or wild-type cdc2
(cdc2wt) affected migration of  3-LNCaP cells on FN (Fig.
3 B) and vitronectin (VN; unpublished data), but had no
effect on adhesion (unpublished data). To establish whether
these results were due to cdc2 effects on cell proliferation,
 3-LNCaP cells transfected with cdc2dn were tested in mi-
gration assays in the presence or absence of an inhibitor of
cell proliferation, mitomycin C. As shown in Fig. 3 B, mito-
mycin C inhibited cell proliferation, but had no effect on
migration in cells transfected with cdc2dn. Ectopic expres-
sion of cdc2dn in LNCaP cells was efficiently achieved by
lipofection (unpublished data).
Two potent and specific inhibitors of cdc2 kinase, purval-
anol A (Gray et al., 1998) and alsterpaullone (Schultz et al.,
1999), were tested to confirm a role for cdc2 in cell migra-
tion. After a 2-h exposure to 0.2 or 1  M purvalanol A, mi-
gration was reduced by more than 30 and 70%, respectively
(Fig. 3 C). Migration was reduced by  50% in cells cul-
tured in the presence of 1.32  M alsterpaullone for 2 h (un-
published data). Neither adhesion nor cell morphology was
significantly or noticeably affected by these concentrations
of inhibitors, as determined by adhesion assays and micro-
scopical analysis, respectively (Fig. 3 C; unpublished data).
*Abbreviations used in this paper: 2D, two dimensional; 3D, three dimen-
sional; FN, fibronectin; IB, immunoblotting; MEF, mouse embryonic
fibroblast; VN, vitronectin; wt, wild type.
Figure 2. cdc2 levels correlate with cell migration. cdc2 protein 
levels in extracts from HT1080 and HT2–19 cells were analyzed by 
IB with an antibody to cdc2 (top left: HT1080 and HT2–19  IPTG; 
middle left: HT2–19  / IPTG). For migration assays (top and middle 
right), 50,000 cells were seeded for 4.5 h, in serum-free medium on 
5  g/ml FN-coated transwell insert filters. After 3.5 h, cells were 
fixed and stained with crystal violet and the cells on the bottom of 
the filter were counted. The mean and SEM of 10 random fields is 
shown (** P   2   10
 8 for HT1080 compared with HT2–19 cells 
 IPTG; * P   2   10
 5 for HT2–19  IPTG compared with HT2–19 
cells  IPTG). For adhesion assays (bottom), 50,000 cells were 
seeded in serum-free medium in a 96-well plate coated with 
increasing concentrations of FN. After 2 h, plates were washed two 
times with PBS, fixed, and stained with crystal violet.T
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In conclusion, inhibition of cdc2 kinase activity prevents cell
migration without affecting cell adhesion.
cdc2 modulates migration of HeLa cells
To investigate whether cdc2 regulates migration in cells other
than LNCaP, cdc2dn and cdc2wt were ectopically expressed
in HeLa cells and their effects on migration and cell cycle
were determined over time. At 24 h, there is a modest reduc-
tion of HeLa cell migration on FN by cdc2dn and a twofold
increase in migration by cdc2wt (Fig. 4 A). Because cdc2 ac-
tivity is regulated by cyclin levels, we tested whether in-
creased levels of cdc2 would be sufficient to increase kinase
levels. Immunoprecipitation of cdc2 from cells transfected
with vector alone or cdc2wt determined that ectopic expres-
sion of cdc2wt increased cdc2 kinase activity (Fig. 4 B). At
48 h, cdc2dn reduces HeLa cell migration more than three-
fold, and cdc2wt increases migration modestly (Fig. 4 A);
neither adhesion nor cell cycle profile was affected by either
cdc2dn or by cdc2wt at these time points (unpublished data).
HeLa cells cultured in the presence of micromolar concentra-
tions of purvalanol A for 2 h show a dose-dependent reduc-
tion of migration on FN with a negligible effect on adhesion
at 8  M (Fig. 4 C). The results show that expression of
cdc2wt and cdc2dn affects HeLa cell migration before a sig-
nificant effect on cell cycle can be observed and that treat-
ment with cdc2 inhibitors blocks HeLa cell migration.
cdc2 is present in peripheral areas of the cell
We investigated whether endogenous cdc2 is associated with
the cytoskeleton of adhering cells and in cells with a motile
phenotype. HeLa cells, plated on FN for 3 h, were incubated
in the presence or absence of 100 nM PMA for 30 min to
induce a motile phenotype (Fig. 4 D; Besson et al., 2001).
In PMA-treated cells, staining of HeLa cells with cdc2 and
ezrin mAbs shows that cdc2 is concentrated in peripheral ar-
eas of the cell, specifically in lamellipodia, and that cdc2 and
ezrin are colocalized (Fig. 4 E). Thus, cdc2 in motile cells is
concentrated in peripheral areas where rapid actin reorgani-
zation occurs; in this cellular location, cdc2 may act on spe-
cific cytoskeleton proteins to modulate cell migration.
Cyclin B2 is the cyclin partner of cdc2 that modulates 
cell migration
Mammalian cdc2 is known to associate with cyclins A, B1,
and B2 (for review see Kohn, 1999). Ectopic expression of
cyclin B2, but not cyclin A or cyclin B1, increased  3-LNCaP
and HeLa cell migration on FN (Fig. 5 A), without affecting
cell adhesion to this substrate (unpublished data). The ec-
topically transfected cyclin B2 was able to form active kinase
complex, as shown by immunoprecipitation kinase assays of
nontransfected versus cyclin B2-transfected HeLa cells using
a cyclin B2 antibody, as well as by immunoprecipitation ki-
Figure 3. cdc2 affects migration of 
 3-LNCaP cells. (A)  3-LNCaP ( 3-2) 
cells cotransfected with pCMV gal and 
pcDNA-3 or pCMVcdc2dn for 60 h 
were harvested and seeded in medium 
containing 0.5% FBS on 10  g/ml 
FN-coated transwell insert filters. After 
6 h, cells were fixed and stained for  gal 
activity and counted as in Materials and 
methods. (B)  3-LNCaP ( 3-2) cells 
cotransfected with pCMV gal and 
pcDNA-3 or pCMVcdc2dn for 60 h 
were incubated in the presence or 
absence of 1  g/ml mitomycin C for 16 h, 
and then harvested and seeded in 
medium containing 10% FBS with or 
without 1  g/ml mitomycin C on 
10  g/ml FN-coated transwell insert 
filters or on 10  g/ml FN-coated 96-well 
plates with 1  Ci [
3H]thymidine per 
well. After 6 h, cells were fixed and 
stained for  gal activity. The number of 
transfected cells that migrated and cells 
that proliferated was calculated as 
described in Materials and methods. 
(C; top) Purvalanol A prevents  3-
LNCaP cell migration.  3-LNCaP cells 
were incubated for 2 h at 37 C in the 
presence or absence of purvalanol A and 
200,000 cells were seeded in medium 
containing purvalanol A at the indicated 
concentrations on 10  g/ml FN-coated 
transwell insert filters. After 6 h, cells 
were fixed and stained with crystal violet 
and the cells on the bottom of the filter were counted. The mean and SEM per square millimeter is shown. (Bottom) Purvalanol A does not 
affect  3-LNCaP cell adhesion to FN.  3-LNCaP cells incubated at 37 C in the presence or absence of purvalanol A for 2 h were trypsinized, 
washed, and 50,000 cells were seeded in medium containing purvalanol A at the indicated concentrations in a 96-well plate coated with FN. 
After 2 h, plates were washed two times with PBS, fixed, and stained with crystal violet. Purv A, purvalanol A. T
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nase assay of cyclin B2 transfected HeLa cells using a c-myc
antibody (Fig. 5 B).
To confirm the role of cyclin B2 in cell migration, mouse
embryonic fibroblasts (MEFs) derived from cyclin B2–null
mice (Brandeis et al., 1998) were compared with their wild-
type (wt) counterparts. Cyclin B2–null MEFs did not signif-
icantly migrate on FN (83% less than wt MEFs); adhesion
to FN was similar for both cell types (Fig. 5 C). These differ-
ences in migration were not due to an increased proliferation
capacity of wt MEFs as compared with cyclin B2–null
MEFs because cyclin B2–null MEFs proliferate more than
wt MEFs (Fig. 5 C). Together, these data implicate cyclin
B2 as the specific cyclin partner of cdc2 that modulates cell
migration.
Caldesmon is a downstream effector of cdc2 in the cell 
motility pathway
Caldesmon, a previously identified mitotic substrate of cdc2
(Mak et al., 1991; Yamashiro et al., 1991), appeared to be a
reasonable candidate downstream of cdc2 in the cell motility
pathway because it is found in membrane ruffles and its abil-
ity to bind actin is reduced upon phosphorylation by cdc2
Figure 4. cdc2 regulates migration of HeLa cells. 
(A) Expression of cdc2dn or cdc2wt affects migration of 
HeLa cells. HeLa cells cotransfected with pCMV gal and 
pcDNA-3, pCMVcdc2dn, or pCMVcdc2wt were trypsinized 
at two different time points (24 and 48 h) after transfection 
and cells were seeded in medium containing 10% FBS on 
10  g/ml FN-coated plates. After 16 h, cells were fixed 
and stained for  gal activity. The mean and SEM of 10 
random fields is shown. (B) Expression of cdc2wt increases 
cdc2 kinase activity. Immunocomplexes precipitated 
from 60  g cell extracts of HeLa cells transfected with 
pcDNA-3 or cdc2wt using an mAb to cdc2 were used 
in a kinase reaction using histone H1 as a substrate. 
(C) Purvalanol A inhibits HeLa cell migration without 
affecting cell adhesion. Migration assays (top): HeLa cells 
were incubated for 2 h at 37 C in the presence or absence of purvalanol A and 90,000 HeLa cells were seeded in medium containing purvalanol A 
at the indicated concentrations on FN-coated transwell insert filters. After 16 h, cells were fixed and stained with crystal violet and the cells 
on the bottom of the filter were counted. The mean and SEM of 10 random fields is shown. Adhesion assays (bottom): 100,000 HeLa cells 
grown in the presence or absence of purvalanol A for 2 h were seeded in medium containing purvalanol A at the indicated concentrations in 
a 96-well plate coated with FN. After 2 h, plates were washed two times with PBS, fixed, and stained with crystal violet. The results show the 
mean and standard deviation of duplicate observations. Purv A, purvalanol A. (D) PMA increases HeLa cell migration. HeLa cells were 
allowed to attach for 1 h to filters coated with 10  g/ml FN and then were incubated in the presence or absence of 100 nM PMA for 3 h and 
processed as described above. The mean and SEM of 10 random fields is shown. (E) cdc2 is enriched in peripheral areas in motile cells. HeLa 
cells plated on 10  g/ml FN-coated coverslips and incubated in the presence of 100 nM PMA were stained with cdc2 mAb (red) and ezrin 
mAb (green); image-merging analysis of ezrin and cdc2 is shown. (Arrows) Peripheral areas of the cell where ezrin and cdc2 colocalize.T
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(Huber, 1997). We tested the migration of HeLa cells ec-
topically expressing cdc2wt in conjunction with either
caldesmon wt or a variant form of caldesmon containing all
seven of its cdc2 phosphorylation sites mutated (“7
th mu-
tant;” Yamashiro et al., 2001). Although caldesmon wt and
cdc2 increased cell migration, caldesmon 7
th mutant and
cdc2 did not have any effect (Fig. 6 A, top); indeed, caldes-
mon 7
th mutant suppressed cdc2-mediated cell migration
(Fig. 6 A, bottom) without affecting cell adhesion (unpub-
lished data), indicating that the mutant caldesmon inhibits
cdc2 activity by competing with the endogenous caldesmon.
It should be noted that expression of exogenous caldesmon
wt and cdc2 had a synergistic effect on cell migration: specif-
ically, motility was increased from 19.4   3% (cdc2 alone)
to 33   7% (cdc2 plus caldesmon). Expression of caldes-
mon wt and of the 7
th mutant was confirmed by immuno-
blotting (IB) analysis (unpublished data).
Next, we confirmed that caldesmon is a substrate of cdc2/
cyclin B2 by immunoprecipitation kinase assay using caldes-
mon immunoprecipitate (Fig. 6 B, cald IP) as a substrate for
cyclin B2 immunocomplexes (Fig. 6 B, B2 IP). These results
implicate cdc2 phosphorylation as an important mechanism
by which caldesmon functions to modulate migration. This
conclusion is also supported by the finding that cdc2 and
caldesmon colocalize in all cells where membrane ruffles were
observed; neither cdc2 nor caldesmon was found by them-
selves in membrane ruffles (Fig. 6 C). In cells not treated
with PMA, the two molecules did not colocalize (Fig. 6 C);
caldesmon was found in stress fibers, in agreement with pre-
vious studies (Huber, 1997; Yamashiro et al., 2001; Fig. 6
C). Together, these results show that caldesmon is a down-
stream effector of cdc2 in the cell–motility pathway.
Discussion
In this paper, we show that cdc2 is a downstream effector of
the  v 3 integrin, and that it controls cell migration. Evi-
dence is provided that exogenous expression of  v 3 integrin
up-regulates cdc2 mRNA and protein levels as well as cdc2
kinase activity and that cdc2 regulates cell migration on inte-
grin ligands without affecting cell adhesion. It is also shown
that cyclin B2 is the cdc2 cofactor that controls cell migra-
tion. Finally, it is shown that caldesmon, a cytoskeleton-
associated molecule known to be phosphorylated by cdc2, is
a substrate for cdc2–cyclin B2 in the migratory pathway,
and colocalizes with cdc2 at the cell periphery and in mem-
brane ruffles in motile cells.
This is the first paper that describes changes in cdc2 levels
in response to integrin expression. Although regulation of cell
cycle–related molecules in response to integrin engagement
has been widely documented (Schwartz and Assoian, 2001),
regulation of the levels of a cdk and of its kinase activity upon
integrin expression has never been reported. Specifically, al-
terations of cdc2 protein levels in response to either integrin
expression or integrin engagement have never been studied.
In one work, cdc2 mRNA levels were shown to remain un-
changed in response to cell adhesion (Guadagno et al., 1993).
However, this analysis was performed in synchronized cells
collected at times corresponding to transit through G1,
whereas our work was performed in asynchronous cell popu-
Figure 5. Expression of cyclin B2 increases cell migration. (A)  3-
LNCaP ( 3-2) and HeLa cells cotransfected with pCMV gal and 
pcDNA-3 (vector), pCMXcyclin A (A), pCMVcyclin B1 (B1), 
or pCMVcyclin B2 (B2) were processed 24 h after transfection, as 
described in Figs. 3 and 4. The mean and SEM of 10 random fields 
is shown. (B) Ectopically expressed cyclin B2 forms active kinase 
complex. Immunocomplexes precipitated from HeLa and cyclin B2–
transfected HeLa RIPA extracts using nonimmune rabbit serum (n.i.), 
or rabbit polyclonal antibody to cyclin B2 (B2) or a c-myc agarose-
conjugated rabbit polyclonal antibody (c-myc) were used in kinase 
assays using histone H1 as a substrate. (C) Cyclin B2–null cells 
migrate poorly on FN. For migration assays (top left panel), 15,000, 
30,000, or 60,000 cyclin B2–null (B2  / ) and wt (B2  / ) MEFs 
were seeded in serum-free medium on 5  g/ml FN-coated transwell 
insert filters. After 4 h, cells were fixed and stained with crystal violet 
and the cells on the top and bottom of the filter were counted. The 
mean and SEM of 10 random fields is shown. For proliferation assays 
(top right panel), 10,000 cells were seeded in serum-free medium 
on 5  g/ml FN-coated 96-well plates in the presence of 1  Ci 
[
3H]thymidine per well. After 4 h, cells were processed to determine 
[
3H]thymidine incorporation, as described in Materials and methods. 
For adhesion assays (bottom panels), 50,000 cells were seeded for 2 h 
in serum-free medium in a 96-well plate coated with increasing 
concentrations of FN as described in Materials and methods.T
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lations. It should be noted that cdc2 protein levels, although
increased in neoplastic cells (Kallakury et al., 1997), do not
vary significantly throughout the cell cycle (Draetta and
Beach, 1988; McGowan et al., 1990; Dalton, 1992; Welch
and Wang, 1992), indicating that the rise of cdc2 seen in
asynchronous populations of  3-LNCaP cells reflects a fun-
damental shift in cdc2 regulation by  v 3.
Although another member of the cdk family, cdk5, has
been shown to play a role in neuronal migration (Homa-
youni and Curran, 2000), this is the first paper identifying
cdc2 as a modulator of cell motility. cdc2 is best character-
ized for its role in promoting cell cycle progression through
the G2/M phase (Pines and Rieder, 2001). In our paper, ex-
perimental conditions where either cdc2dn or cdc2 inhibi-
tors affected cell migration, but did not affect cell prolifera-
tion, were established in all cell types; the long doubling
time of LNCaP cells facilitated the initial discrimination be-
tween cell migration and cell proliferation.
We demonstrate that the mechanism by which cdc2 regu-
lates cell migration is via its specific association with cyclin
B2. This claim is based on several experimental findings:
first, cdc2 is localized in lamellipodia of motile cells; this is a
novel finding because previous reports had analyzed cdc2
distribution in nonmotile cells and shown at interphase to
be distributed both in the nucleus and the cytoplasm (Bailly
et al., 1989; Pockwinse et al., 1997). Second, ectopic expres-
sion of cyclins B1, B2, and A, all known to associate with
cdc2 (for review see Pines, 1999) shows that only cyclin B2
has the ability to increase cell migration. Finally, cyclin B2–
null cells display significantly reduced cell migration, al-
though their proliferation rates are not reduced. Indeed,
subcellular localization of mitotic cdc2 by cyclins B1 and B2
Figure 6. Caldesmon is a downstream effector of 
cdc2 in the cell motility pathway. (A) Coexpression 
of cdc2 and caldesmon wt, but not caldesmon 7
th 
mutant, increases HeLa cell migration (top). Caldesmon 
7
th mutant inhibits cdc2-mediated HeLa cell migration 
(bottom). HeLa cells cotransfected with pCMV gal 
and empty vector, or pCMVcdc2wt and pCMV myc-
tagged caldesmon wt (cald wt) or pCMVcdc2wt 
and pCMV myc-tagged caldesmon with seven 
mutated cdc2 phosphorylation sites (7
th mut; top) 
or pCMVcdc2wt alone or pCMVcdc2wt and pCMV 
myc-tagged caldesmon 7
th mutant (7
th mut; bottom) 
were processed as above, 24 h after transfection 
(** P   2   10
 5, top; ** P   10
 4 bottom). The mean 
and SEM of 10 random fields is shown. (B) Caldesmon 
is a substrate of cdc2/cyclin B2. (Left) Caldesmon 
immunoprecipitated from HeLa cells or H1 was used 
as substrate of either recombinant cdc2/cyclin B1 
or cyclin B2 immunocomplexes in kinase assays. 
(Middle) An equivalent amount of caldesmon 
immunoprecipitate used in the kinase assay, and 3  g 
histone H1, were separated using SDS-PAGE and stained with Coomassie blue. (Right) Immunoblot of caldesmon immunoprecipitate using 
SM12 mAb to caldesmon. Cald IP, caldesmon immunoprecipitate. (C) HeLa cells plated on 10  g/ml FN-coated coverslips and incubated in 
the presence or absence of 100 nM PMA were stained with caldesmon mAb and cdc2 mAb. Image-merging analysis of caldesmon (green) 
and cdc2 (red) indicates yellow patches where superposition of the two molecules is particularly noted (see also arrows). (Arrows) Peripheral 
areas of the cell where caldesmon and cdc2 colocalize.T
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has been shown to confer substrate specificity (Draviam et
al., 2001). Thus, it is conceivable that the cdc2–cyclin B2
complex will also provide specificity for the substrate(s) that
modulates a nonmitotic event like cell migration. We rea-
soned that the cdc2 substrate that is likely to mediate cdc2’s
effect on cell motility would be colocalized with cdc2.
Among the mitotic substrates for cdc2 that are known to be
associated with the cytoskeleton: dynein, caldesmon, plectin,
and zyxin (Mak et al., 1991; Yamashiro et al., 1991; Malecz
et al., 1996; Dell et al., 2000; Hirota et al., 2000), caldes-
mon was a strong candidate to mediate cdc2’s effect on cell
migration for two main reasons. First, caldesmon is associ-
ated with cytoskeletal structures such as stress fibers and
membrane ruffles, and has been shown to interfere with fo-
cal contact formation; second, its actin binding ability is re-
duced upon phosphorylation by cdc2 (Yamakita et al.,
1992; Yamashiro et al., 1995, 2001; Huber, 1997; Helfman
et al., 1999). Our paper shows that caldesmon, indeed,
modulates cell motility downstream of cdc2 and that phos-
phorylation by cdc2 is a crucial step in this motility path-
way. It also shows that caldesmon and cdc2 colocalize in
membrane ruffles, sites of rapid reorganization of actin. In
these sites, cdc2 phosphorylation of caldesmon may affect
actin reorganization during cell migration by modulating
caldesmon’s actin-binding ability (Yamashiro et al., 1990,
1991, 1995; Yamakita et al., 1992) and, potentially, focal
contact formation (Helfman et al., 1999).
Previous observations showed that  v 3 expression is de-
tected only in prostate cancer, but not in normal prostate
epithelial cells (Zheng et al., 1999). Our data suggest that
 v 3 integrin and its downstream effector, cdc2, may be im-
portant mediators of prostate cancer progression toward an
aggressive metastatic phenotype. This conclusion is sup-
ported also by data reported by Kallakury et al., indicating
that cdc2 is expressed in a majority of prostatic adenocarci-
nomas and correlates with high Gleason’s grade, advanced
pathologic stage, and metastatic adenocarcinomas (Kalla-
kury et al., 1997). Changes in gene expression during pro-
static metastatic spread in vivo are likely to occur as recently
shown for RhoC in melanoma cells (Clark et al., 2000). In
conclusion, the functional role of cdc2 in prostate cancer in
vivo may be different than once thought; it may reflect the
migratory, rather than the proliferative, ability of these cells.
Materials and methods
Cells
LNCaP cell populations stably transfected with the pRc/CMV expression
vector alone (mock) or containing human  3 integrin cDNA ( 3-1) or
ICAM-1 cDNA (ICAM) have been described (Zheng et al., 1999). In this
paper, two additional  3 populations ( 3-2 and  3-3) and two  6 LNCaP
clones transfected with human  6 integrin cDNA (Sheppard et al., 1990)
were generated. Expression of  v 6 integrin was confirmed by FACS
® anal-
ysis using the 10D5 mAb; mouse IgG was used as a negative control. HeLa
and HT1080 cells were obtained from American Type Culture Collection.
HT2–19 cells (Itzhaki et al., 1997) were a gift of Dr. A.C.G. Porter (Medical
Research Council, London, UK). Cyclin B2–null and wt MEFs (Brandeis et
al., 1998) were provided by Dr. T. Hunt (Imperial Cancer Research Fund,
South Mimms, Herts, UK). For 3D cultures, cells were resuspended in
Matrigel at a cell density of 10
6 cells/ml. For biochemical analysis, 3D cul-
tures were detached from Matrigel by incubating with Matrisperse. For
biochemical analysis or gene expression profiles, two-dimensional (2D)
cultures were detached by trypsinization or, in parallel with the 3D cul-
tures, by using Matrisperse (1 h on ice). Alternatively, 2D cultures were
lysed directly on the plate.
Cell adhesion assays
Adhesion assays were performed as described previously (Languino et al.,
1989).
RNA isolation and analysis
Gene expression profiles of  3-1, ICAM, and mock LNCaP cells were gen-
erated using Atlas Human Cancer cDNA Expression arrays (CLONTECH
Laboratories, Inc.) according to the manufacturer’s instructions. Northern
blot analysis was performed using total RNA from 2D and 3D cell cultures
isolated using TRIzol Reagent (GIBCO BRL). The 231-bp cdc2 cDNA frag-
ment corresponding to the fragment on the cDNA array was generated by
PCR. The cDNA fragment was amplified using the primers 5 -GGGT-
CAGCTCGTTACTCAACTCCAG-3  and 5 -GACATGGGATGCTAGGCT-
TCCTGGT-3  and human cdc2 cDNA as template. A 780-bp human
GAPDH cDNA was excised from pGEM-3zf ( ) with BamHI and PstI.
Immunoblotting and in vitro kinase assays
Cells were lysed using RIPA buffer (with 50 mM sodium fluoride for lysates
to be used in in vitro kinase assays), either directly on the plate after wash-
ing with PBS, or after detaching with Matrisperse, as described for the 3D
cultures above. For HT1080 and HT2–19 cells, cells were lysed as de-
scribed (Itzhaki et al., 1997).
Primary antibodies to cdc2 (mAb, sc-54), to c-myc (mAb 9E10 and rab-
bit polyclonal agarose conjugate) and to ERK-1 (rabbit polyclonal that
cross reacts with ERK-2, sc-94) were from Santa Cruz Biotechnology, Inc.
Rabbit antiserum to cyclin B2 was a gift from J. Pines (Wellcome/Cancer
Research Campaign Institute and Department of Zoology, Cambridge,
UK). Caldesmon mAb SM12 was a gift from F. Matsumura (Rutgers Univer-
sity, Piscataway, NJ). Immunoprecipitation of cdc2 and in vitro kinase as-
says were performed essentially as described (Draetta and Beach, 1988;
Morla et al., 1989; Pines and Hunter, 1989; Yu et al., 1998). 60 or 75  g
precleared cell lysate was used for immunoprecipitation using 2  g mAb
sc-54 or mouse IgG for 1 h, followed by protein A–Sepharose (Sigma Fast
Flow) for 1 h. After two washes with lysis buffer and one wash with kinase
buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10 mM MgCl2, 0.5 mM
DTT, 0.2 mM sodium orthovanadate, 0.1 mM sodium fluoride), immuno-
precipitates were incubated in 20  l kinase buffer with 250  g/ml histone
H1, 25  M ATP, 62.5  Ci/ml [ -
32P]ATP for 30 min at 30 C, stopped by
the addition of loading buffer, heated at 98 C for 5 min, separated on 12%
SDS-PAGE, and visualized by autoradiography.
For cyclin B2 immunoprecipitation-kinase assays, cyclin B2 was immu-
noprecipitated from HeLa RIPA extracts with a cyclin B2 rabbit polyclonal
antibody as described (Jackman et al., 1995) and incubated with histone
H1 as described in the preceding paragraph, or with caldesmon immuno-
precipitated from HeLa cells. Caldesmon was immunoprecipitated as de-
scribed (Wang et al., 1999) except that, because caldesmon is heat stable,
the lysate was boiled and clarified by centrifugation before immunoprecip-
itation by mAb SM12. Specifically, 5   10
6 HeLa cells were lysed with 50
mM Hepes, pH 7.5, 1% Triton X-100, 1% NP-40, 0.5% deoxycholate, 50
mM NaCl, 5 mM EDTA, 0.1 mM sodium vanadate, 1 mM PMSF, 10  g/ml
aprotinin, 10  g/ml leupeptin, centrifuged 14,000 g for 10 min. The super-
natant was then boiled for 5 min, cooled on ice for 30 min, and centri-
fuged 14,000 g for 10 min. An equal volume of immunoprecipitation
buffer A (2.5% Triton X-100, 50 mM Tris-HCl, pH 7.4, 6 mM EDTA, 190
mM NaCl) was added to the supernatant, which was then precleared with
protein A–Sepharose. Caldesmon mAb SM12 was added to the precleared
lysate. After 1 h on ice, protein A–Sepharose was added and samples were
rocked at 4 C for 1 h. Immunoprecipitates were washed three times with
buffer B (150 mM NaCl, 10 mM Tris-HCl, pH 9, 5 mM EDTA, 0.1% Triton
X-100) and once with kinase buffer (described in the preceding para-
graph). Caldesmon immunoprecipitates were then used as substrate for ei-
ther cyclin B2 immunocomplexes or recombinant cdc2/cyclin B1 (New
England Biolabs, Inc.).
Migration assays
 3-LNCaP,  6-LNCaP, and HeLa cells were transiently cotransfected with a
1:7 ratio of pCMV- gal and pcDNA-3 (empty vector), pCMVcdc2dn-HA,
or pCMVcdc2wt-HA (van den Heuvel and Harlow, 1993).  3-LNCaP and
HeLa cells were also transfected with pCMV- gal and pCMX cyclin A,
pCMV cyclin B1, or pCMV cyclin B2. HeLa cells were also transfected
with pCMV- gal and pCMVcdc2wt-HA and either 3  g pCMV rat non-
muscle caldesmon wt or 3  g pCMV rat nonmuscle caldesmon 7
th mutantT
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(Yamashiro et al., 2001). Lipofectamine 2000 (GIBCO BRL) was used as
the transfection reagent. 1–3 d after transfection, the cells were seeded on
8- m pore-sized transwell filter inserts (Costar) coated with 5 or 10  g/ml
FN or 3  g/ml VN. In parallel, transiently transfected cells were also
seeded on FN, VN, and poly-L-lysine–coated plates to measure their ability
to adhere to these substrates. After 6 h, cells were fixed with 0.2% glutaral-
dehyde, washed with TTBS, and stained for  gal using x-gal as substrate
(400  g/ml x-gal, 0.5 mM K4Fe[CN]6, 0.5 mM K3Fe[CN]6, 1 mM MgCl2 in
PBS), at 37 C for 2 h. The number of transfected cells in 10 random fields
on the top and the bottom were counted for each filter. The percentage (av-
erage and SEM) of the attached transfected cells ( gal-positive cells on the
top and bottom of the filter) that migrated ( gal-positive cells on the bottom
of the filter) was calculated.
 3-LNCaP,  6-LNCaP, HT1080, HT2–19 cells, cyclin B2–null, and wt
MEFs were seeded on 5- m (HT1080, HT2–19), 8- m ( 3-LNCaP,  6-
LNCaP), or 12- m (cyclin B2–null MEFs, wt MEFs) pore-sized transwell
filter inserts coated with 5 or 10  g/ml FN or 3  g/ml VN. After 4 h
(HT1080, HT2–19, cyclin B2–null MEFs, wt MEFs) or 6 h ( 3-LNCaP,  6-
LNCaP), cells were fixed with 3% PFA/PBS, stained with crystal violet, and
the number of cells per square millimeter on the bottom were counted (av-
erage and SEM of 10 random fields).
For cells cultured in the presence or absence of alsterpaullone and pur-
valanol A (Calbiochem) for 2 h, cells were seeded on filters as above in the
absence or presence of alster or purvalanol A, for 6 h ( 3-LNCaP) or 16 h
(HeLa), and counted as described in the preceding paragraph. In parallel,
cell adhesion assays in the presence of alster or purvalanol A were per-
formed; cells were seeded in 96-well plates coated with 1–10  g/ml FN or
3  g/ml VN for 2 h, fixed with 3% PFA/PBS, stained with crystal violet,
and the absorbance at 630 nm measured.
For cells cultured in the presence of mitomycin C (Sigma-Aldrich; 16-h
incubation), cells were trypsinized and seeded on filters as above in the
absence or presence of mitomycin C. After 6 h, cells were stained for  gal
and the number of cells per square millimeter on the top and bottom were
counted (average and SEM of 10 random fields).
Proliferation assays
For cells cultured in the presence of mitomycin C (Sigma-Aldrich; 16-h in-
cubation), cells were trypsinized and seeded on FN-coated 96-well plates,
in triplicate, in the presence of 1  Ci [
3H]thymidine in 100  l medium per
well (in the presence or absence of mitomycin C), and incubated for 6 h.
Medium was then removed, and cells were washed three times with PBS,
solubilized with 10% SDS, and the amount of [
3H]thymidine incorporated
by the cells was quantitated by scintillation counting.
Immunofluorescence microscopy
HeLa cells were seeded on 10  g/ml FN-coated coverslips, incubated in
the presence or absence of 100 nM PMA and fixed with 3% PFA, 2% su-
crose, pH 7.6 for 10 min at room temperature. Coverslips were stained
with mAb to cdc2 (A17, IgG2kappa; Zymed), mAb to L-caldesmon (Clone
8, IgG1; BD Biosciences) and mAb to ezrin (Clone 18, IgG1; BD Bio-
sciences). Secondary antibodies were class-specific goat anti–mouse IgGs
coupled to either FITC or Texas red (Southern Biotechnology Associates,
Inc.). In some single staining experiments, we also used a different mAb to
caldesmon (SM12) and obtained essentially identical results. Nonbinding
mouse IgGs were used as a control. Nuclear staining was performed with
Hoechst 33342. 200 cells were systematically analyzed and  30% cells
showed changes in morphology upon PMA treatment.
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